ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
53 announcements with these filters
Jeena Sikho Lifecare signed an agreement to establish a research institute in Chandigarh at no cost. This strengthens its R&D ecosystem in Ayurveda and preventive wellness.
Jeena Sikho Lifecare Limited plans to set up a new 160‑bed hospital in Lucknow, costing around ₹3 Crore. The internal‑funded expansion enhances its healthcare network.
Jeena Sikho Lifecare Limited is establishing a new daycare clinic in Ayodhya with a ₹0.50 Crore investment. Expected to commence in August 2026, this expansion strengthens its healthcare network.
Jeena Sikho Lifecare commenced operations at its new 100-bed Ayurvedic hospital in Mathura. The facility strengthens its healthcare infrastructure and supports long-term operational growth.
Jeena Sikho delivered strong FY26 results with 71% revenue growth and 177% PAT growth, driven by hospital utilization and high-margin product sales. Management targets 4-5x PAT growth over 3-5 years.
Jeena Sikho reported stellar FY26 growth, pivoting from government to high-margin private patients. Management used flamboyant, messianic rhetoric to mask ₹21cr in one-time expenses related to auditor-mandated accounting changes and staff bonuses.
Jeena Sikho reported stellar FY26 performance with Revenue at ₹80,135 Lakhs and PAT at ₹22,218 Lakhs. The company expanded to 2,300 operational beds across 119 centers.
Jeena Sikho reported strong Q4FY26 results with a 55% YoY revenue surge, driven by expanding Ayurveda healthcare services and product reach.
Jeena Sikho Lifecare Limited re-appointed Forvis Mazars LLP as Internal Auditor for a twelve-month term. The board-approved appointment ensures continuity in the company's internal audit function.
Jeena Sikho Lifecare recommended a final dividend of ₹4.5 per equity share for the period. The board will announce the record date and general meeting schedule later.
Jeena Sikho Lifecare Ltd reported revenue from operations of ₹215.6 Cr (+54.8% YoY) and net profit of ₹45.1 Cr (+78.3% YoY) for Q4 FY26.
Jeena Sikho Lifecare approved FY26 audited results and recommended a Rs. 4.50 per share dividend. Strong annual performance supports the payout, pending final shareholder approval.
Jeena Sikho Lifecare Limited filed its Annual Secretarial Compliance Report for FY26. The report confirms overall regulatory adherence with minor observations regarding past disclosure delays.
Jeena Sikho Lifecare announced the publication of thirteen Ayurvedic case studies in international medical journals. This highlights the company's commitment to evidence-based clinical research and practice.
Jeena Sikho Lifecare scheduled a board meeting for May 30, 2026. Directors will consider FY2026 audited financial results and recommend a final dividend.
Jeena Sikho Lifecare approved selling 48 Bigha of non-operational land for ₹24.0 Crore. The transaction improves liquidity with no impact on existing business operations.
Jeena Sikho Lifecare approved selling 48 Bigha of non-operational land for ₹24.0 Crore. The transaction to Tresco Realty Group LLP will not impact business operations.
Jeena Sikho Lifecare Limited has appointed GoIndia Advisors LLP as its Investor Relations Management Agency. The agency will provide investor and public relations management services to the company. The appointment is effective from May 04, 2026, and aims to enhance the company's communication with the investor community.
Jeena Sikho Lifecare Limited announced the publication of seven case studies and two case reports in the Journal of Applied Science and Education. Authored by the company's medical professionals, these publications focus on Ayurvedic treatments for chronic kidney disease, sciatica, and osteoarthritis, highlighting the company's commitment to evidence-based clinical research.
Jeena Sikho Lifecare Limited confirmed it does not qualify as a 'Large Corporate' for FY 2025-26 under SEBI's framework. The company reported outstanding borrowings of ₹0.43 Crore as of March 31, 2026, staying below the regulatory threshold for mandatory debt market issuance.
Jeena Sikho Lifecare Limited received NABH accreditation for its Noida Hospital for Panchakarma services. The certification (AH-2026-0451) is valid until March 09, 2029. This accreditation signifies adherence to national quality standards for healthcare delivery and patient safety without constituting a business expansion or acquisition.
Jeena Sikho Lifecare Limited signed a three-year strategic MOU with Sat Kartar Life Limited to integrate patient acquisition systems with clinical infrastructure. The partnership includes a 15% revenue sharing model on OPD and IPD cases. This collaboration aims to enhance healthcare delivery efficiency and expand footprint, particularly in South India.
Jeena Sikho Lifecare Ltd submitted a compliance certificate for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent confirmed that no physical shares were received for dematerialization during this period, fulfilling routine SEBI reporting obligations.